Pentagamaboronon-0 Fructose Inhibited Migration and Overexpression of Matrix Metalloproteinases 9 on MCF-7/HER2 Breast Cancer Cells

Indah Hairunisa, Rohmad Yudi Utomo, Yogi Ertanto, Riris Istighfari Jenie, Edy Meiyanto

Abstract


The incidence of Breast Cancer Metastasis (MBC) can be categorized in stage IV as well as being the leading cause of death in cases of breast cancer. MBC prognosis is known to be weak, frequent recurrent, and MBC patients have only a survival rate of about 5 years. One of the proteins that causes breast cancer metastasis is Human Epidermal Growth Factor 2 (HER2). Pentagamaboron-0 (PGB-0), a newly curcumin analogue performed cytotoxic effect on HER2-positive breast cancer cells but it is practically water-insoluble. The aims of this study are to determine anti-metastatic activity of a more soluble form of PGB-0 namely PGB-0 fructose complex (PGB-0-F) toward HER2 positive cancer (MCF-7/HER2) cells. PGB-0-F was obtained from Cancer Chemoprevention Research Centre Faculty of Pharmacy Universitas Gadjah Mada. Based on scratch wound healing assay result, PGB-0-F inhibited cell migration especially in combination with doxorubicin at the concentration 15 μM. Under gelatin zymography assay, PGB-0-F in combination with doxorubicin decreased Matrix Metalloproteinases 9 (MMP-9) expression compare to the doxorubicin. Hence, PGB-0-F has a potency to be developed as anti-metastatic agent on HER2 overexpression breast cancer.

Keywords : HER2, MCF-7/HER2, PGB-0-F, Metastasis


Full Text:

PDF

References


Amalina, N.D., Nurhayati, I.P., and Meiyanto, E., 2017, Doxorubicin Induces Lamellipodia Formation and Cell Migration, Indones. J. Cancer Chemoprevent., 8(2), 61-67. CrossRef

American Cancer Society and National Comprehensive Cancer Network, 2006, Breast Cancer Treatment and Guidelines Version VIII/September 2006, Atlanta: American Cancer Society Inc.

Donovan, D., 2013, Metastatic Breast Cancer Epidemiology and Management With a Focus on Taxanes, Clin. J. Oncol. Nurs., 17(1), 5-8.

CrossRef

Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al., 2012, Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012, Int. J. Cancer, 136(5), E359–386. CrossRef

Furuya, M., Horiguchi, J., Nakajima, H., Kanai, Y., and Oyama, T., 2011, Correlation of L-type Amino Acid Transporter 1 and CD98 Expression with Triple Negative Breast Cancer Prognosis., Cancer Sci., 103(2), 382-389. CrossRef

Gibbs, J.B., 2000, Anticancer Drug Targets: Growth Factors and Growth Factor Signaling, J. Clin. Invest., 105(1), 9–13. CrossRef

Gonzalez-Angulo, A.M., Morales-Vasquez, F., and Hortobagyi, G.N, 2007, Overview of Resistance to Systemic Therapy in Patients with Breast Cancer, Adv. Exp. Med. Biol., 608, 1-22. CrossRef

Holliday, D.L. and Speirs, V., 2011, Choosing the Right Cell Line for Breast Cancer Research, Breast Cancer Res., 13(4), 215. CrossRef

Hudish, C., 2007, Trastuzumab — Mechanism of Action and Use in Clinical Practice, N. Engl. J. Med., 357(1), 39-51. CrossRef

Kemenkes RI, 2015, Pusat Data dan Informasi Kementrian Kesehatan RI, Stop Kanker, Jakarta: Kementrian Kesehatan RI Pusat Data dan Informasi. Link

Kurebayashi, J., 2001, Biological and Clinical Significance of HER2 Overexpression in Breast Cancer, Breast Cancer, 8(1), 45-51. CrossRef

Lemmen, J.G., Arends, R.J., van Boxtel, A.L., van der Saag, P.T., and van der Burg, B., 2004, Tissue- and Time-dependent Estrogen Receptor Activation in Estrogen Reporter Mice, J. Mol. Endocrinol., 32(3), 689–701. Link

Meiyanto, E., Supardjan A.M., and Da’i, M., 2003, Antiproliferative Effect of PGV-0 A Curcumin Analogue Against HeLa Cells, Gama Sains, 5(3), 200-206.

Meiyanto, E., Supardjan, Muhammad, D., and Agustina, D., 2006, Antiproliferative Effect of Pentagamavunon-0 on Breast Cancer Cell Line T47D, Jurnal Kedokteran Yarsi, 14(1), 11-15. Link

Meiyanto, E., Supardjan, Muhammad, D., and Agustina, D., 2007, Pentagamavunon-0 Induces Apoptosis on T47D Breast Cancer Cell Line through Caspase-3 Activation, Jurnal Kedokteran Yarsi, 15(2), 75-79. Link

Meiyanto, E., Putri, D.D., Susidarti, R.A., Murwanti, R., Sardjiman, Fitriasari, A., et al., 2014, Curcumin and Its Analogues (PGV-0 and PGV-1) Enhance Sensitivity of Resistant MCF-7 Cells to Doxorubicin through Inhibition of HER2 and NFkB Activation, Asian Pac. J. Cancer Prev., 15(1), 179-84. CrossRef

O’Shaughnessy, J., 2015, Extending Survival with Chemotheraphy in Metastatic Breast Cancer, Oncologist, 10(Suppl 3), 20-29. CrossRef

Pedrycz, A. and Kramkowska, A., 2016, Adriamycin - Efficacy and Possible Adverse Effects, Curr. Probl. Psychiatry, 17(1), 38–46. CrossRef

Putri, H., Jenie, R.I., Handayani, S., Kastian, R.F., and Meiyanto, E., 2016. Combination of Potassium Pentagamavunon-0 and Doxorubicin Induces Apoptosis and Cell Cycle Arrest and Inhibits Metastasis in Breast Cancer Cells, Asian Pac. J. Cancer Prev., 17(5), 2683–2688. CrossRef

Scully, O.J., Bay, B.H., Yip, G. and Yu, Y., 2012, Breast Cancer Metastasis, Cancer Genomics Proteomics., 9(5), 311-320. Link

Siegel, R.L., Miller, K.D., and Jemal, A., 2018, Cancer Statistics, CA. Cancer J. Clin., 68(1), 7-30. CrossRef

Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., and McGuire, W.L, Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene, Science, 235(4785),177-182. CrossRef

Utomo, R.Y., Putri, H., Pudjono, Susidarti, R.A., Jenie, R.I and Meiyanto, E., 2017, Synthesis and Cytotoxic Activity of 2,5-BIS (4-Boronic Acid) Benzylidine Cyclopentanone on HER2 Overexpressed-Cancer Cells, Indonesian J. Pharm., 28(2), 74-81. CrossRef

Yao, D., Dai, C. and Peng, S., 2011, Mechanism of the Mesenchymal–Epithelial Transition and Its Relationship with Metastatic Tumor Formation, Mol. Cancer Res., 9(12), 1608-1620. CrossRef

Zhao, S., Ohara, S., Kanno, Y., Midorikawa, Y., Nakayam, M., Makimura, M., et al., 2013, HER2 Overexpression-mediated Inflammatory Signalling Enhances Mammosphere Formation through Up-regulation of Aryl Hydrocarbon Receptor Transcription, Cancer Lett., 330(2013), 41-48. CrossRef




DOI: http://dx.doi.org/10.14499/indonesianjcanchemoprev9iss3pp%25p

Copyright (c) 2018 Indah Hairunisa

Indexed by:

               

                  

         

 

Indonesian Society for Cancer Chemoprevention